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Introduction
It goes without saying now that there is a 
severe risk to health world wide because of the 
continued emergence of resistance of bacteria 
to many of the currently available antibacterial 
drugs. About 12 years ago at Strathclyde we 
began a project to see whether it would be 
possible to transform the oligoamide natural 
products, distamycin (1) and netropsin (2), into 
useful antibiotics by modifying their structures 
so that toxicity and unwanted biological activity 
was removed and selective, high antibiotic 
activity obtained. These natural products were 
well known to bind to the minor groove of DNA 
DQGGHWDLOVRIWKHFRQ¿JXUDWLRQRIELQGLQJZHUH
NQRZQIURP;UD\FU\VWDOORJUDSK\>@$¿UP
basis therefore existed for the design of new 
minor groove binding ligands. The research 
plan was to introduce additional hydrophobic 
components into the ligands so that binding to 
the non-polar regions of the minor groove could 
be obtained and so that the physicochemical 
properties of the new compounds be made 
more drug-like than those of distamycin and 
netropsin. These were new concepts at the time 
(Figure 1). However it was known that the 
sequence selectivity of binding of oligoamide 
natural products was tunable by including 
N-methylimidazole at positions where binding 
adjacent to a GC base pair was required because 
substitution of the pyrrole CH by N removed a 
steric clash between ligand and minor groove 
[3]. The ability of large synthetic ligands to bind 
with high selectivity to extended sequences 
of DNA has been exploited outstandingly by 
Dervan and his colleagues [4]. The Strathclyde 
approach in contrast was to concentrate on 
smaller compounds of up to 700 D and to 
vary structure by changes in head group, alkyl 
substituent, and tail group (Figure 2).
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Figure 1
Getting to grips with drug-like minor groove 
binders
,Q WKH ¿UVW SKDVH RI WKH ZRUN VWXGLHV ZHUH
aimed at learning how different structural 
PRGL¿FDWLRQVZRXOGLQÀXHQFHELQGLQJWR'1$
and biological activity. For the former, capillary 
electrophoresis and footprinting were primary 
techniques and for the latter, routine assays 
were run against a short panel of Gram-positive 
and Gram-negative bacteria and fungi. This 
led to a number of design principles that could 
be used to invent compounds with potentially 
useful properties as follows [5]:
 N- and C-alkyl substituents up to C5, 
including branched chains, were acceptable 
for DNA binding and led to antibacterial 
and antifungal activity provided that they 
were not attached to adjacent rings of the 
oligoamides;
 Bulky head groups such as t-butyl prevented 
binding and gave biologically inactive 
compounds;
 1,5-dimethyl substitution in pyrrole 
oligomers prevented binding and gave 
biologically inactive compounds;
 Substantial variation was possible in the 
structure of the amino tail group;
 Whereas the inclusion of imidazoles (polar) 
led to toxic ligands, GC reading could be 
established using thiazoles (non-polar) in 
accordance with the initial design plan.
Figure 2
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The most detailed work was carried out with a 
compound known as thiazotropsin A (3, Figure 
2), which contained a  C-isopropylthiazole and a 
GLPHWK\ODPLQRHWK\OWDLOJURXSDVPRGL¿FDWLRQV
of the distamycin structure. Thiazotropsin 
$ GLG VKRZ VLJQL¿FDQW DQWLEDFWHULDO DFWLYLW\
(IC
50 
~ 5µM against a range of Gram-positive 
bacteria) but its main value was as a pilot 
compound that taught how such small ligands 
with potentially useful biological activity bind 
to DNA. Professor Keith Fox (University of 
Southampton) used footprinting techniques 
to show that thiazotropsin A had a strongly 
preferred binding site (ACTAGT) [5] and this 
sequence was incorporated into decamers and 
dodecamers for further investigations of DNA 
binding [6]. The dissociation constant for binding 
to an oligonucleotide containing ACTAGT was 
determined by isothermal calorimetry as 50 
Q0DQG LWZDV IXUWKHU VKRZQ WKDW WKLVDI¿QLW\
was 100-fold greater than to an oligonucleotide 
containing ATATAT. NMR studies using both 
chemical shift changes on ligand binding and 
NOE experiments provided clear evidence for 
the structure of the complex [7]: thiazotropsin A 
bound in a ratio of 2 molecules of ligand to the 
PLQRU JURRYH LQ DQ DQWLSDUDOOHO FRQ¿JXUDWLRQ
such that the thiazole ring was adjacent to G and 
DVSHFL¿FK\GURJHQERQGZDVIRUPHGEHWZHHQ
the thiazole N and the guanosine NH
2
. In order 
to accommodate two molecules of ligand, the 
PLQRU JURRYH EURDGHQHG VLJQL¿FDQWO\ VXFK
D FKDQJH ZRXOG EH H[SHFWHG WR LQÀXHQFH WKH
conformation of DNA not just locally but 
allosterically at sites not directly interacting 
with the ligand. Interestingly, the coverage 
of thiazotropsin A of 6 base pairs is a similar 
OHQJWK WR VHTXHQFHV LGHQWL¿HG DV VLJPD IDFWRU
promoter binding in bacterial gene expression 
(see below).
Discovery leading to MGB-BP3
With this knowledge available, further 
PRGL¿FDWLRQV ZHUH LQWURGXFHG DW WKH KHDG
group consistent with the design model (Figure 
Chemistry & Biology Interface, 2015, 5, 3, 166-174
Figure 3 (DUO\KLWVLQWURGXFLQJPDMRUPRGL¿FDWLRQVWRWKHGLVWDP\FLQVWUXFWXUHDQGWKHVWUXFWXUDO
change (isosteric replacement of amide by alkene) that led to the discovery of MGB-BP3.
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1) and to create more sites for medicinal 
FKHPLFDOPRGL¿FDWLRQ3ULQFLSDODPRQJVWWKHVH
was the use of aromatic head groups. Including 
VXFKVXEVWUXFWXUHVVLJQL¿FDQWKLWVZHUHIRXQG
for both antibacterial and antifungal activity 
(Figure 3). At this stage it was decided to 
concentrate upon antibacterial activity and what 
WXUQHGRXWWREHWKHNH\VWUXFWXUDOPRGL¿FDWLRQ
was introduced. In order to increase further 
the non-polar interactions, it would be worth 
investigating whether an alkene, the non-
polar isostere of an amide, could be used as 
a link between the component rings of the 
minor groove binder. This change led to AIK 
¶¿UVWSUHSDUHGE\'U$EHGDZQ.KDODI
in 2006, and now known as MGB-BP3 (Figure 
3) [8].
In making this change it was clear that a 
potential hydrogen bonding site would be lost 
but there could be compensation from non-polar 
interactions. Moreover, the alkene link would 
not be susceptible to hydrolysis and importantly 
IRUVXEVHTXHQWELRORJLFDOVWXGLHVDÀXRURSKRUH
ZDVLQWURGXFHG&RQ¿UPDWLRQRIVWURQJELQGLQJ
to DNA for the alkene class of compound was 
obtained by melting temperature measurements 
ZKLFKVKRZHGQRORVVRIDI¿QLW\WRWKHGRGHFDPHU
GCGATATATGCG/CGCTATATACGC. Many 
compounds with alkene links to the head group 
showed substantial antibacterial activity with 
very little evidence for mammalian cell toxicity 
EXW0*%%3ZDVVLJQL¿FDQWO\WKHPRVWDFWLYH
having an MIC less than 1 µg/ml against many 
Gram-positive bacteria. 
Gram-negative activity, however, was not 
Chemistry & Biology Interface, 2015, 5, 3, 166-174
Figure 4 Summary of structure-activity for MGB-BP3-like compounds against Gram-positive 
bacteria.
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observed. It could be argued that it might be 
possible to replace one of the other amide links 
by an alkene also. With some effort, examples 
of such compounds were synthesized with 
the alkene between Het 2 and Het 3 (using 
WKH ODEHOLQJ LQ )LJXUH  6LJQL¿FDQWO\ QRQH
of these compounds was found either to bind 
strongly to DNA or to have antibacterial activity. 
The use of an alternative isostere, the diazo 
JURXSGLGQRWJLYHFRPSRXQGVZLWKVLJQL¿FDQW
antibacterial activity or DNA binding [8a]. A 
further indication of the special characteristics 
of MGB-BP3 was found by removing the 
quinoline nitrogen atom to give a naphthalene 
head group, moving it to give an isoquinoline, 
or adding additional nitrogen atoms; none 
of these changes led to strongly antibacterial 
compounds. A summary of the structure-activity 
relationships established for antibacterial 
DFWLYLW\LVVKRZQLQ)LJXUH3DWHQWVZHUH¿OHG
IRUDOORIWKHVLJQL¿FDQWGLVFRYHULHV>@
At this point in the project the University of 
6WUDWKFO\GH SXW LQ D VLJQL¿FDQW HIIRUW WR ¿QG
a commercial partner for the development of 
these discoveries. A deal was done in 2010 
to license the two patents to a new Scottish 
company, MGB Biopharma. This company 
has subsequently raised money and managed 
the development of MGB-BP3 to reach Phase 
 FOLQLFDO WULDOV LQ  6XEVWDQWLDO VFLHQWL¿F
support has been provided by the University 
of Strathclyde, the vast majority of which has 
been funded by internal University funds and 
UK research council grants. The remainder 
RI WKLV SDSHU FRQFHQWUDWHV XSRQ WKH VFLHQWL¿F
results that have supported the development 
programme with reference to formulation, 
selectivity, and mechanism of action.
Selectivity of MGB-BP3 and related 
compounds
A key property of the MGB-BP3 class of 
antibacterial compound is their selectivity for 
Gram-positive bacteria and their lack of apparent 
activity against mammalian cells. This is well 
illustrated by data from another compound of the 
class, AIK 20/25/1, which is almost as active as 
MGB-BP3 and is the second compound in line 
for development. Figure 5 shows the effect on 
cellular viability for this compound comparing 
DPDPPDOLDQFHOOOLQH+6PXULQH¿EUREODVW
with Staphylococcus aureus. The difference is 
striking. No evident toxicity was found with the 
HS27 cells but catastrophic death was found for 
the bacteria. Similar results have been obtained 
for many compounds in this series. The 
catastrophic bactericidal activity is not typical 
of a drugs acting at a single pharmacological 
Chemistry & Biology Interface, 2015, 5, 3, 166-174
Figure 5 Selectivity for Gram-positive bacteria shown by a close relative of MGB-BP3
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target but suggests that the minor groove 
binders exert their effect by interfering with a 
number of biochemical pathways that together 
lead to catastrophic death; this will be discussed 
further below.
As was noted above, the MGB-BP3 class 
of antibacterial compound did not show 
VLJQL¿FDQW DFWLYLW\ DJDLQVW *UDPQHJDWLYH
EDFWHULD 1HYHUWKHOHVV VRPH VLJQL¿FDQW KLWV
were obtained in particular with compounds 
containing thiazoles and with amidine-linked 
head groups such as MGB-BP4 (Figure 6). 
It was important to establish the reasons for 
these differences. Taking advantage of the 
LQWULQVLFÀXRUHVFHQFHRIWKH0*%%3FODVVRI
compounds, it was possible to show that MGB-
BP3 readily entered the cells of Gram-positive 
EDFWHULDEXWQRXSWDNHRIÀXRUHVFHQFHZDVVHHQ
in Gram-negative bacteria.
Figure 6 A hit, MGB-BP4, in a screen for anti-
Gram-negative compounds
However when E. coli cells were treated 
with lysozyme and EDTA so that the outer 
cell membrane was removed and so-called 
spheroplasts were formed, intracellular 
ÀXRUHVFHQFHZDVREVHUYHG>@7KHFRQFOXVLRQ
that penetration of the cells is necessary for 
activity is obvious. It was shown later that a 
major contribution to the failure of the MGB-
BP3 family to attach Gram-negative bacteria 
ZDV GXH WR HIÀX[ SXPSV :KHQ FHOOV RI
Pseudomonas aeruginosa were treated with 
ERWK DQ HIÀX[ SXPS LQKLELWRU 3KH$UJȕ
naphthylamide) and a minor groove binder, 
VRPHFRPSRXQGVZHUHIRXQGWREHVLJQL¿FDQWO\
active. As this work was proceeding, the 
activity of the Strathclyde minor groove binders 
against other infectious organisms, particularly 
parasites, was also being investigated. Different 
FRPSRXQGV VKRZHG GLVWLQFW DFWLYLW\ SUR¿OHV
In summary the following activities have been 
found: in vitro against Candida albicans and 
Asperg illusniger; in vitro against Plasmodium 
falciparum DD3, a drug resistant strain;in vitro 
against Trypanosoma brucei (human parasite) 
and in vivo against Trypanosoma congolense 
(animal parasite); in vivo against Leishmania 
major and Leishmania donovani. Now these 
parasites are all eucaryotes and again selectivity 
with respect to mammalian cells was found. 
This point is emphasised by the successful 
proof of concept experiments with animals in 
models of sleeping sickness and leishmaniasis 
in which effective minor groove binders did not 
show toxicity to the animals at therapeutically 
HIIHFWLYH GRVHV >@ $ JHQHUDO VLJQL¿FDQW
VFLHQWL¿F SRLQW FDQ EH LGHQWL¿HG IURP WKHVH
results, namely that the toxicity of a minor 
groove binder depends not only upon its ability 
to bind to DNA but also on the way in which the 
target cell handles the drug. To put it simply, if 
the drug does not enter the cell, it cannot reach 
DNA to exert its effect. What reaches the DNA 
LV HYLGHQWO\ ERWK FRPSRXQG VSHFL¿F DQG FHOO
VSHFL¿F
These concepts can now be examined in terms 
of the antibacterial minor groove binders such 
as MGB-BP3. MGB-BP3 clearly is able to 
enter Gram-positive bacterial cells as shown 
E\ÀXRUHVFHQFHPLFURVFRS\2QWKHRWKHUKDQG
there is no evidence for the penetration of BP3 
into a number of mammalian cell lines that have 
been studied, including B16FOluc (mouse lung 
carcinoma) and A549 (human lung carcinoma).
Now these are all cell lines in which membrane 
FRPSRQHQWV VXFK DV HIÀX[ SXPSV PD\ QRW
be as active as in primary cells. Both primary 
macrophages and primary hepatocytes have 
been examined and in neither case was MGB-
Chemistry & Biology Interface, 2015, 5, 3, 166-174
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BP3 found to enter these cells. The experiments 
were shown to be competent because other 
minor groove binders such as Hoechst dyes were 
found to enter the cells and to concentrate in the 
nuclei [12]. It therefore seems that by chance 
MGB-BP3 has a favourable combination of 
properties to act as an antibacterial drug, namely 
selective penetration of the target bacterial cell 
DQGKLJKDI¿QLW\ IRU'1$$WWHQWLRQFDQQRZ
turn to the consequences of DNA binding in the 
bacterial cell.
Mechanism of action of MGB-BP3
In order to understand the effect of MGB-
BP3 as an anti-Gram-positive compound, 
the modern technique of RNA-seq has been 
used. In these experiments, Staphylococcus 
aureus cells were treated with MGB-BP3 at 
a sub-lethal concentration so that its effect on 
cellular biochemistry could be determined by 
the differential expression of genes compared 
with an untreated sample as shown in the 
transcriptome [13]. Large quantities of data 
were generated and it is important to establish 
WKH VLJQL¿FDQFH RI WKH GDWD 7KHUHIRUH WZR
independent experiments have been carried 
out at increasing sequencing depth and the data 
analysed by four software methods. Several 
hundred genes have been found to be either up- 
or down-regulated, including about 70 essential 
genes, and the response of S. aureus has now been 
characterised. For example it was not surprising 
WR¿QG WKDW WKHJHQHHQFRGLQJ WKHKLVWRQHOLNH
protein that protects the bacterial chromosome 
was substantially up-regulated on challenge 
by MGB-BP3. Other notable changes were the 
down-regulation of phosphomevalonate kinase, 
DQHQ]\PHWKDWKDVEHHQLGHQWL¿HGDVDSRWHQWLDO
drug target. When all of the changes were 
transferred to a metabolic map for S. aureus 
the areas of greatest effect were nucleic acid 
and nucleic acid component metabolism (up 
and down), lipid metabolism (mostly up), and 
glycolysis and oxidative phosphorylation (up 
DQGGRZQ,QWHUPVRIWKHNLOOFXUYHV¶SUR¿OHVWKH
implication that a catastrophic failure in energy 
production leads to cell death is attractive. In 
RUGHUWRLQFUHDVHFRQ¿GHQFHLQWKHVLJQL¿FDQFH
of these observations, a number of enzymes 
was selected and the change in their expression 
investigated by qRT-PCR. In summary it was 
found that the qRT-PCR data set matches the 
RNA-seq data set with respect to relative gene 
expression levels between different genes, that 
the qRT-PCR matches the RNA-Seq data set 
with respect to the effect of MGB-BP3, and that 
some genes analysed by qRT-PCR are essential 
genes in S. aureus.
A further point arising from the RNA-seq 
experiments is that the target sites for binding 
0*%%3WR'1$ZHUHLGHQWL¿HG&RQVHQVXV
sequences of AT rich sites were found 
consistent with the known binding of MGB-
BP3 to DNA from footprinting experiments. 
MGB-BP3 showed especially strong footprints 
at AT rich sequences such as TTTAAACGTT 
and ATATATGTATA [14]. The binding sites 
LGHQWL¿HG E\ 51$VHT ZHUH 7$$*$* DQG
AAAGAAAA. Together these data point to a 
variety of AT rich sites that are competent for 
binding to MGB-BP3. It is interesting that a 
recent study also using RNA-seq drew attention 
to a number of AT rich sites as promoter binding 
sites in S. aureus,of which TATAGT, TATAAA, 
TAAAAT, TATTTT, TATAAT, and TATACT 
were highlighted [15]. The probability that 
MGB-BP3 exerts its gene expression modifying 
and hence antibacterial effects by binding to 
some of these promoter sequences is strong.
Formulation of MGB-BP3
Clinical trials of course refer to a medicine and not 
simply to an active pharmaceutical ingredient. 
MGB Biopharma has invested heavily in the 
development of MGB-BP3 into a medicine and 
has brought it to the stage of a Phase 1 clinical 
trial in an oral formulation for the treatment of 
&ORVWULGLXPGLI¿FLOHinfections. The probability 
is that MGB-BP3 exerts its antibacterial effects 
Chemistry & Biology Interface, 2015, 5, 3, 166-174
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by modifying gene expression through binding 
to some of these promoter sequences.
The underlying science for formulation has also 
been studied at the University of Strathclyde. 
Although MGB-BP3 is dibasic, its pK
a
s are 
low, 3.49 (quinoline) and 5.26 (morpholine) 
indicating that at physiological pH greater than 
99% of the molecules will be neutral. In order 
to obtain aqueous formulations, it is necessary 
to maintain a pH of about 5. The low pK
a
 of 
the morpholine is especially striking being at 
least 2.5 below a typical N-alkyl morpholine. 
It was also observed that when a solution of 
MGB-BP3 and its close relatives was brought 
from pH 3 towards pH 7, turbidity appeared at 
about pH 5 and, if allowed to stand, the solution 
transformed into a gel. The gel returned to 
mobile solution on gentle warming. A possible 
explanation for these phenomena is that MGB-
BP3 and its close relatives form dimers in 
DTXHRXV VROXWLRQ VLPLODU WR WKH FRQ¿JXUDWLRQ
found in DNA binding (Figure 1). Direct 
evidence for this possibility came from an 
NMR study of the MGB-BP3 analogue with 
a 3-methoxyphenyl head group in place of the 
3-quinolyl head group (Figure 7) [16]. 
Figure 7 Self association of an MGB-BP3 
relative as shown by NOE studies in aqueous 
solution.
At room temperature substantially broad signals 
were observed but at 80 oC it was possible to 
obtain well-resolved [1H] spectra for this 
compound and also to measure NOE effects. 
As shown in Figure 7, NOEs were observed 
consistent with the existence of antiparallel 
GLPHUV RI H[DFWO\ WKH VDPH FRQ¿JXUDWLRQ WKDW
would bind to DNA according to the design 
paradigm for the Strathclyde compounds.
Conclusion
MGB-BP3 has been developed up to Phase I by 
MGB Biopharma. It is highly effective against
Gram-positive bacteria but not Gram-negative 
bacteria. Nevertheless, a number of hits have 
been found in the Strathclyde MGB library with 
activity against Gram-negative bacteria and a 
hit to lead programme of research for Gram-
negative activity is now under way. Further,proof 
of concept experiments with other Strathclyde 
MGBs in animal models for parasitic diseases 
have been successful supporting the case for 
Strathclyde MGBs as a discovery platform for 
anti-infective medicines of many types. With 
respect to the mechanism of action of the lead 
antibacterial drug, MGB-BP3, evidence has 
accrued that itcauses a substantial biochemical 
and physiological response in S. aureus 
consistent with DNA binding in particular at 
promoter sites. Other experiments suggest 
that the selectivity for bacterial compared with 
mammalian cells probably relates to differential 
access to cells. This is obviously of crucial 
importance for MGB-BP3 and other MGBs 
as drugs of the future and it isa problem under 
active investigation.
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